IDEXX Laboratories Inc (IDXX) company profile
Close on Nov 18, 2026Market cap $55.03BP/E 49.1Yield –
About IDEXX Laboratories
In Vitro & In Vivo Diagnostic Substances, SIC 2835
IDEXX Laboratories, Inc. develops, manufactures, and distributes diagnostic products and services primarily for companion animal veterinary care, livestock, poultry, dairy, and water testing. Operating through its Companion Animal Group, Water quality products, Livestock, Poultry and Dairy, and human diagnostics segments, the company serves veterinarians, biomedical researchers, livestock producers, water utilities, and diagnostic laboratories. Its offerings include point-of-care analyzers, consumables, rapid assays, reference laboratory services, practice management software, diagnostic imaging, and microbiological water tests.
The company maintains a commercial presence across North America, Europe, Asia Pacific, Latin America, and Africa. It operates a network of approximately 80 reference laboratories serving clients across countries including the United States, Canada, Australia, Japan, New Zealand, South Africa, and South Korea. IDEXX operates manufacturing and distribution facilities in Westbrook and Scarborough, Maine; Roswell, Georgia; Memphis, Tennessee; as well as the Netherlands, Switzerland, France, and the United Kingdom.
Summary of the business section of IDEXX Laboratories's latest annual report, written by StockData.
Company profile
Company
- Legal name
- IDEXX Laboratories Inc
- Founded
- 1983
- Headquarters
- Westbrook, ME
- Address
- One Idexx Drive 04092-2041
- Phone
- (207) 556-0300
- Website
- www.idexx.com
- Employees
- 11,000, Dec 31, 2025
- Industry
- In Vitro & In Vivo Diagnostic Substances
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- IDXX
- Exchange
- Nasdaq
- IPO date
- Jun 21, 1991
- Shares outstanding
- 79M, Jul 31, 2026
- Public float
- $42.90B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Jun 16, 2015; 2-for-1, Nov 27, 2007; 2-for-1, Jun 6, 1995; 2-for-1, Oct 4, 1993
- SEC CIK
- 874716
- CUSIP
- 45168D104
- ISIN
- US45168D1046
- FIGI
- BBG000BLRT07
- Share class FIGI
- BBG001S5S4Y9
- LEI
- OGMTXK0LUU1HKV2P0J84
- EIN
- 01-0393723
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jonathan Jay Mazelsky | Executive Chair of the Board, Director | 83,803 |
| George Fennell | Executive Vice President | 12,182 |
| Michael Lane | Executive Vice President | 4,668 |
| Sharon E. Underberg | EVP, GC & Corporate Secretary | 7,169 |
| Andrew Emerson | EVP, CFO and Treasurer | 4,507 |
| Nimrata Hunt | Executive Vice President | 18,301 |
| Michael G. Erickson | Executive Vice President | 15,092 |
| Michael Perkins Johnson | Executive Vice President | 2,795 |
| Martin Alexander Smith | Executive Vice President | 1,603 |
| Michael Schreck | Executive Vice President | 2,123 |
| Brian P. McKeon | EVP, CFO and Treasurer | 49,600 |
| Daniel M. Junius | Director | 2,361 |
| Joseph L. Hooley | Director | 373 |
| Lawrence D. Kingsley | Director | 9,568 |
| Irene Chang Britt | Director | 208 |
| Bruce L. Claflin | Director | 1,721 |
| Sam Samad | Director | 0 |
| Stuart Essig | Director | 2,236 |
| Karen Peacock | Director | 102 |
| Sophie V. Vandebroek | Director | 9,078 |
| M. Anne Szostak | Director | 2,320 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $14.58M | $31.76M | $3.06M | $135 | $148 |
| FY2024 | $13.01M | $2.33M | $3.77M | $83 | $129 |
| FY2023 | $11.52M | $22.68M | $3.31M | $111 | $126 |
| FY2022 | $9.79M | -$13.75M | $2.78M | $82 | $124 |
| FY2021 | $9.07M | $28.21M | $2.85M | $132 | $126 |
| FY2020 | $7.04M | $34.87M | $2.31M | $191 | $113 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Jonathan J. Mazelsky President and Chief Executive Officer | $1.15M | $5.40M | $5.40M | $2.59M | $37.24K | $14.58M | +12% |
| Andrew Emerson Executive Vice President and Chief Financial Officer | $531.15K | $949.86K | $949.94K | $577.50K | $24.62K | $3.03M | – |
| Michael J. Lane Executive Vice President and General Manager, CAG Diagnostics Business Unit | $594.05K | $1.35M | $1.35M | $627.27K | $98.29K | $4.02M | +8% |
| Tina Hunt Executive Vice President, Global Strategy and Commercial | $594.05K | $1.35M | $1.35M | $627.27K | $24.17K | $3.95M | +6% |
| Martin Smith Executive Vice President and Chief Technology Officer, R&D, Global Operations, Information Technology and Information Security | $594.05K | $1.35M | $1.35M | $627.27K | $23.41K | $3.94M | +6% |
| Brian P. McKeon Former Executive Vice President, Chief Financial Officer and Treasurer | $293.40K | – | – | – | $58.28K | $351.68K | -91% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had approximately 11,000 regular full-time and part-time employees in approximately 34 countries around the world, and men and women represented 41% and 59%, respectively, of our global employee population.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 6, 2007 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
See a number that looks wrong?